Hepatic Cell News 4.16 May 8, 2020 | |
| |
TOP STORYScientists showed that hepatocyte-specific loss of the gluconeogenic enzyme fructose 1,6-bisphosphatase 1 (FBP1) disrupted liver metabolic homeostasis and promoted tumor progression. FBP1 was universally silenced in both human and murine liver tumors. [Nat Cell Biol] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers found tripartite motif-containing 27 (TRIM27) to be a key regulator of hepatic ischemia/reperfusion injury by mediating the degradation of TRIM27-TGF-β–activated kinase 1 (TAK1) binding protein 2/3 and the suppression of downstream TAK1-JNK/p38 signaling. [Hepatology] Abstract RNA m6A Methylation Regulates Sorafenib Resistance in Liver Cancer through FOXO3-Mediated Autophagy The authors revealed a critical function for METTL3-mediated N6-methyladenosine (m6A) modification in the hypoxic tumor microenvironment and identified FOXO3 as an important target of m6A modification in the resistance of hepatocellular carcinoma to sorafenib therapy. [EMBO J] Full Article Researchers combined mouse liver progenitor cells (LPCs) with mouse liver sinusoidal endothelial cells (LSECs) to generate hepatobiliary organoids with liver-specific vasculature. Organoids consisting of 5×103 cells were created from either LPCs, or a 1:1 combination of LPC/LSECs. [Biomaterials] Abstract The β-Catenin/TCF-4-LINC01278-miR-1258-Smad2/3 Axis Promotes Hepatocellular Carcinoma Metastasis A novel mechanism for β-catenin/TCF-4-LINC01278-miR-1258-Smad2/3 feedback loop activation in hepatocellular carcinoma (HCC) metastasis was uncovered, and long non-coding RNA LINC01278 was identified as a therapeutic target for HCC metastasis. [Oncogene] Full Article By detecting CD133+ cells and carrying out sphere culture assays, investigators found that knockdown of the N6-methyladenosine (m6A) reader, YTHDF2, led to impaired stemness in hep3b and huh7 cells. [Oncogene] Abstract Scientists discovered that neddylation of sterol regulatory element-binding protein 1c (SREBP1c) competed with its ubiquitination and stabilized SREBP1c protein level, eventually promoting hepatic steatosis. [Cell Death Dis] Full Article The authors found that the DEAD/DEAH box helicase 11 (DDX11) was overexpressed in hepatocellular carcinoma tissues. High DDX11 expression was positively correlated with large tumor size, tumor multiplicity, late tumor-node-metastasis stage and poor prognosis. [Cell Death Dis] Full Article Researchers compared methods for the quantification of immunoreactive N-acetyltransferase 1 (NAT1) and N-acetyltransferase 2 (NAT2) and showed that NAT2 activity in human hepatocytes was directly correlated to expression levels of NAT2 protein, but not mRNA. [Sci Rep] Full Article Loss of SRSF2 Triggers Hepatic Progenitor Cell Activation and Tumor Development in Mice Investigators demonstrated that loss of Srsf2 triggered hepatic progenitor cell-mediated regeneration and activation of oncofetal genes, which altogether promoted hepatocellular carcinoma development and progression in mice. [Commun Biol] Full Article Subscribe to one of our other 19 science newsletters such as Intestinal Cell News & Pancreatic Cell News. | |
| |
REVIEWSOncogenic Driver Genes and Tumor Microenvironment Determine the Type of Liver Cancer The authors provide a summary of the possible mechanisms for directing the cancer phenotype of liver tumors in terms of oncogenic driver genes and tumor microenvironment, as well as reveal the cell origin of different types of liver cancer. [Cell Death Dis] Full Article Highly Upregulated in Liver Cancer (HULC): An Update on its Role in Carcinogenesis Investigators summarize the recent literature about the role of HULC in the carcinogenesis and its potential application in cancer diagnosis and prognosis. [J Cell Physiol] Abstract Visit our reviews page to see a complete list of reviews in the hepatic cell research field. | |
| |
INDUSTRY NEWSHighTide Therapeutics, Inc. have announced topline results of the study of HTD1801 in 100 adults with non-alcoholic steatohepatitis and type 2 diabetes mellitus. HTD1801 demonstrated broad beneficial effects in measures of glycemic control, liver injury and cardiovascular risk factors. [HighTide Therapeutics, Inc. (Business Wire, Inc.)] Press Release | |
| |
POLICY NEWS‘It Will Not Be Easy’ as Labs Begin to Reopen, Enormous Challenges Remain One of the biggest challenges labs face is how to keep their members physically distanced to limit any potential spread of SARS-CoV-2. [ScienceInsider] Editorial Coronavirus: Share Lessons on Lifting Lockdowns Countries are starting to lift restrictions on movement, but there is little consensus on how this should be done. Sharing best practice is the way forward. [Nature News] Editorial
| |
EVENTSIn light of COVID-19, many conferences are being cancelled or postponed. As such: We are suspending new event postings in our newsletters and on Twitter. Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Scientist – Quantitative Biology (Texas Biomedical Research Institute) NEW Research Scientist – Liver (Spark Therapeutics) Staff Fellow – Viral Vaccines (FDA-Center for Biologics Evaluation and Research) Postdoctoral Fellow – Molecular Diagnostics and Experimental Therapeutics (City of Hope) Professorship of Hepatology (Ludwig-Maximilians-Universität) Senior Research Scientist – Liver Disease (Novo Nordisk) Scientist – Molecular & Cellular Biology (Deep Genomics, Inc.) Postdoctoral Position – Gut-Liver Axis (University of California, Davis) Therapuetic Specialist – Inflammation (Gilead Sciences Inc.) Team Leader – Cholangiocytes (Miromatrix Medical) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hepatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|